Chidamide monotherapy for the treatment of hepatosplenic T-cell lymphoma: A case report / 中国输血杂志
Chinese Journal of Blood Transfusion
; (12): 628-630, 2021.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-1004500
Responsible library:
WPRO
ABSTRACT
【Objective】 To generate an efficacious therapeutic plan for patients suffered from Hepatosplenic T-cell lymphoma (HSTCL). 【Methods】 A patient diagnosed as HSTCL in January 2016 was observed, and chidamide monotherapy instead of traditional chemotherapy was applied due to the poor performance and infection complications of the patient. 【Results】 The patient has achieved amazing improvements after chidamide monotherapy. As we followed and evaluated recently, the patient has received partial remission and can keep durable remission for 4 years. 【Conclusion】 The study suggests that chidamide is a novel therapeuticchoice in patients with HSTCL.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Chinese Journal of Blood Transfusion
Year:
2021
Document type:
Article